v3.26.1
Segment Information - Summary of Financial Data for Company's Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting Information [Line Items]            
Research and development expenses $ 53,435   $ 26,846   $ 107,119 $ 46,633
General and administrative expenses 10,113   3,817   20,932 7,573
Other segment items [1] (3,356)   (818)   (7,191) (2,021)
Net loss 60,192 $ 60,668 29,845 $ 22,340 120,860 52,185
Clinical trial            
Segment Reporting Information [Line Items]            
Research and development expenses 20,716   5,987   45,535 7,926
Employee related            
Segment Reporting Information [Line Items]            
Research and development expenses 16,836   6,958   32,829 14,008
General and administrative expenses 5,774   1,902   12,764 3,962
Chemistry, manufacturing and controls expenses            
Segment Reporting Information [Line Items]            
Research and development expenses 6,331   3,404   12,748 7,360
Preclinical program            
Segment Reporting Information [Line Items]            
Research and development expenses 8,294   9,727   13,816 15,808
Professional fees            
Segment Reporting Information [Line Items]            
General and administrative expenses 4,339   1,915   8,168 3,611
Other segment            
Segment Reporting Information [Line Items]            
Research and development expenses $ 1,258   $ 770   $ 2,191 $ 1,531
[1] Other segment items include interest income and other income, net.